Suppr超能文献

多中心全球早期可行性研究,以评估使用三血管内分支支架移植物进行主动脉弓全腔内修复治疗动脉瘤和夹层的效果。

Multicenter global early feasibility study to evaluate total endovascular arch repair using three-vessel inner branch stent-grafts for aneurysms and dissections.

作者信息

Tenorio Emanuel R, Oderich Gustavo S, Kölbel Tilo, Dias Nuno V, Sonesson Björn, Karelis Angelos, Farber Mark A, Parodi F Ezequiel, Timaran Carlos H, Scott Carla K, Tsilimparis Nikolaos, Fernandez Carlota, Jakimowicz Tomasz, Jama Katarzyna, Kratzberg Jarin, Mougin Justine, Haulon Stéphan

机构信息

Department of cardiothoracic and vascular surgery, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Tex.

Department of cardiothoracic and vascular surgery, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Tex.

出版信息

J Vasc Surg. 2021 Oct;74(4):1055-1065.e4. doi: 10.1016/j.jvs.2021.03.029. Epub 2021 Apr 16.

Abstract

OBJECTIVE

We evaluated the outcomes of total endovascular aortic arch repair using three-vessel inner branch stent-grafts for aneurysms and chronic dissections.

METHODS

We reviewed the clinical data and outcomes of consecutive patients treated by total endovascular aortic arch repair at eight academic centers using three-vessel inner branch stent-grafts (William Cook Europe, Bjaeverskov, Denmark) from 2016 to 2019. All patients received three-vessel designs with two antegrade and one retrograde inner branch, which was used to incorporate the innominate, left common carotid, and left subclavian arteries. The antegrade inner branches were accessed via a carotid or an upper extremity approach. A preloaded catheter was used for access to the retrograde left subclavian artery branch via a transfemoral approach. The endpoints were technical success, mortality, major adverse events, any stroke (minor or major) or transient ischemia attack, secondary interventions, target vessel patency, target vessel instability, aneurysm-related mortality, and patient survival.

RESULTS

A total of 39 patients (31 men [79%]; mean age, 70 ± 7 years) had undergone treatment of 14 degenerative (36%) and 25 chronic (64%) postdissection arch aneurysms. The clinical characteristics included American Society of Anesthesiologists class ≥III in 28 patients (95%) and previous median sternotomy for ascending aortic repair in 28 patients (72%). The technical success rate was 100%. Two patients had died in-hospital or within 30 days (5%), and two patients had experienced a stroke (one minor). The combined mortality and any stroke rate was 8% (n = 3). Major adverse events occurred in 10 patients (26%), including respiratory failure in 4 (10%) and estimated blood loss >1 L, myocardial infarction, and acute kidney injury in 2 patients each (5%). The median follow-up was 3.2 months (interquartile range, 1-14 months). Of the 39 patients, 12 (31%) required secondary interventions to treat vascular access complications in 5, endoleak in 6 (three type II, one type Ic, one type Ia/Ib, one type IIIa), and target vessel stenosis in 1 patient. At 1 year, the primary and secondary patency rates and freedom from target vessel instability were 95% ± 5%, 100%, and 91% ± 5%, respectively. Freedom from aortic-related mortality and patient survival was 94% ± 4% and 90% ± 6%, respectively.

CONCLUSIONS

The findings from the present multicenter global experience have demonstrated the technical feasibility and safety of total endovascular aortic arch repair for aneurysms and chronic dissections using three-vessel inner branch stent-grafts. The mortality and stroke rates compare favorably with those after open surgical repair in a higher risk group of patients. However, the rate of secondary interventions was high (31%), emphasizing need for greater experience and longer follow-up.

摘要

目的

我们评估了使用三分支内支架型人工血管进行全腔内主动脉弓修复治疗动脉瘤和慢性夹层的效果。

方法

我们回顾了2016年至2019年在八个学术中心接受使用三分支内支架型人工血管(丹麦比耶沃斯科夫的威廉·库克欧洲公司)进行全腔内主动脉弓修复治疗的连续患者的临床资料和治疗效果。所有患者均接受三分支设计,其中两个顺行内分支和一个逆行内分支,用于纳入无名动脉、左颈总动脉和左锁骨下动脉。顺行内分支通过颈动脉或上肢入路进入。使用预加载导管通过经股动脉入路进入逆行左锁骨下动脉分支。观察终点包括技术成功率、死亡率、主要不良事件、任何卒中(轻度或重度)或短暂性脑缺血发作、二次干预、靶血管通畅情况、靶血管稳定性、动脉瘤相关死亡率和患者生存率。

结果

共有39例患者(31例男性[79%];平均年龄70±7岁)接受了治疗,其中14例(36%)为退行性病变,25例(64%)为慢性夹层后弓部动脉瘤。临床特征包括美国麻醉医师协会分级≥III级的患者有28例(95%),既往因升主动脉修复行正中胸骨切开术的患者有28例(72%)。技术成功率为100%。2例患者在住院期间或30天内死亡(5%),2例患者发生卒中(1例轻度)。死亡率和任何卒中发生率的总和为8%(n = 3)。10例患者(26%)发生主要不良事件,包括4例(10%)呼吸衰竭,2例患者(5%)估计失血量>1L、心肌梗死和急性肾损伤。中位随访时间为3.2个月(四分位间距,1 - 14个月)。在39例患者中,12例(31%)需要二次干预,其中5例用于治疗血管入路并发症,6例用于治疗内漏(3例II型,1例Ic型,1例Ia/Ib型,1例IIIa型),1例用于治疗靶血管狭窄。1年时,一级和二级通畅率以及无靶血管不稳定的比例分别为95%±5%、100%和91%±5%。无主动脉相关死亡率和患者生存率分别为94%±4%和9%±6%。

结论

本次多中心全球经验的结果表明,使用三分支内支架型人工血管进行全腔内主动脉弓修复治疗动脉瘤和慢性夹层在技术上是可行的且安全的。在高危患者组中,死亡率和卒中率与开放手术修复后的结果相比具有优势。然而,二次干预率较高(31%),强调需要更多经验和更长时间的随访。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验